Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 35,378 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: alone Clear all
Active, not recruiting Phase 3 Interventional

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

NCT04444921
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Recurrent Anal Squamous Cell Carcinoma, Stage III Anal Cancer AJCC v8, Stage IV Anal Cancer AJCC v8, Unresectable Anal Squamous Cell Carcinoma
Interventions
Carboplatin, Nivolumab, Paclitaxel
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
579
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 381 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Oxycodone Hydrochloride 30 mg Tablets and Roxicodone™ 30 mg Tablets

NCT00853216
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone hydrochloride tablet 30 mg, Roxicodone™ tablet 30 mg
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Nov 10, 2026, 4:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Health Benefits of Workplace Policies and Practices - Phase II

NCT02050204
View directory record Official record
Conditions
Focus of Study: Work Conditions
Interventions
Intervention
Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
Not listed
Enrollment
2,753 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Nov 10, 2026, 4:45 AM EST
Active, not recruiting Phase 1 Interventional

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284
View directory record Official record
Conditions
Neoplasms
Interventions
Dostarlimab
Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
48
States / cities
Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 10, 2026, 4:45 AM EST
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

NCT00567047
View directory record Official record
Conditions
Type-2 Diabetes
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Nov 10, 2026, 4:45 AM EST
Completed No phase listed Observational Results available

Human Use Condition Study- Evaluation of Implanted Leads in Humans

NCT04320849
View directory record Official record
Conditions
Pacemaker Malfunction
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Des Moines, Iowa • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Nov 10, 2026, 4:45 AM EST
Completed Not applicable Interventional

Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer

NCT02703493
View directory record Official record
Conditions
Cancer of the Oropharynx
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1 Interventional

Intrauterine Lidocaine for Laminaria

NCT01541293
View directory record Official record
Conditions
Abortion, Induced, Pain Management
Interventions
Lidocaine, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Nov 10, 2026, 4:45 AM EST
Completed Not applicable Interventional Results available

UroLift System TOlerability and ReCovery When Administering Local Anesthesia

NCT01876706
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift® System
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
San Diego, California • Daytona Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Nov 10, 2026, 4:45 AM EST
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Behavioral Pharmacology of THC and Beta-Myrcene

NCT05432284
View directory record Official record
Conditions
Cannabis Use
Interventions
Placebo, THC, Beta-Myrcene
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1Phase 2 Interventional Results available

RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration

NCT03633084
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
RBM-007 Injectable Solution
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Sacramento, California • Stanford, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 10, 2026, 4:45 AM EST
Terminated Not applicable Interventional

Contrast Enhanced Ultrasound vs. Computed Tomographic Angiography in the Detection of Endoleaks Following AAA Repair

NCT01230684
View directory record Official record
Conditions
Endograft Implantation to Repair Abdominal Aortic Aneurysm
Interventions
Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Nov 10, 2026, 4:45 AM EST
Completed Not applicable Interventional Results available

Evaluation of WIRION™ EPS in Lower Extremities Arteries

NCT02780349
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD)
Interventions
WIRION
Device
Lead sponsor
Gardia Medical
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Denver, Colorado • Davenport, Iowa • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Nov 10, 2026, 4:45 AM EST
Recruiting Phase 2 Interventional

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions
ROC-101
Drug
Lead sponsor
AllRock Bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 10, 2026, 4:45 AM EST
Recruiting Not applicable Interventional

Craniomaxillofacial and Upper Extremity Allotransplantation

NCT04057638
View directory record Official record
Conditions
Face Injuries, Hand Injuries, Craniofacial Injuries, Upper Extremity Injuries, Facial Injuries, Facial Deformity
Interventions
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 10, 2026, 4:45 AM EST
Recruiting Phase 1Phase 2 Interventional

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

NCT06306638
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy, Interstitial Photodynamic Therapy, Palliative Radiation Therapy, Physical Performance Testing, Questionnaire Administration, Verteporfin, Laser: ML7710-PDT
Procedure · Radiation · Other + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 2 Interventional

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

NCT01236638
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

NCT05496738
View directory record Official record
Conditions
Healthy
Interventions
PF-07264660 intravenous single ascending dose, PF-07264660 subcutaneous multiple ascending dose, Intravenous placebo, subcutaneous placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Garden Grove, California • Long Beach, California • Los Alamitos, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD5847 After Multiple Doses Over 14 Days

NCT01116258
View directory record Official record
Conditions
Healthy
Interventions
AZD5847, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2010 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 3 Interventional

Telephone and Web-based Teen Tobacco Cessation in HMOs

NCT00311948
View directory record Official record
Conditions
Tobacco Use
Interventions
Telephone counseling + interactive website = more abstinence, Behavioral: interactive website
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
15 Years to 18 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Eugene, Oregon • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Nov 10, 2026, 4:45 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Clinical Guidelines for Opioid Prescribing

NCT04044521
View directory record Official record
Conditions
Opioid Use
Interventions
Systems consultation
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Green Bay, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Nov 10, 2026, 4:45 AM EST
Completed Phase 2 Interventional

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT05888233
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Interventions
Allopurinol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 10, 2026, 4:45 AM EST